搜尋
Inovio Pharmaceuticals Inc
INO添加自選
1.220USD
+0.030+2.52%
收盤 07/02, 13:00（美東）報價延遲15分鐘
84.18M總市值
虧損本益比TTM
關於 Inovio Pharmaceuticals Inc 公司
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Inovio Pharmaceuticals Inc簡介
公司代碼INO
公司名稱Inovio Pharmaceuticals Inc
上市日期Dec 08, 1998
CEOShea (Jacqueline Elizabeth)
員工數量134
證券類型Ordinary Share
年結日Dec 08
公司地址660 W. Germantown Pike
城市PLYMOUTH MEETING
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編19462
電話18584103134
網址https://www.inovio.com/
公司代碼INO
上市日期Dec 08, 1998
CEOShea (Jacqueline Elizabeth)
Inovio Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
111.02K
+23.43%
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
87.59K
--
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.82K
+14.79%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
43.23K
+14.37%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
--
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
111.02K
+23.43%
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
87.59K
--
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.82K
+14.79%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
43.23K
+14.37%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
--
常見問題
Inovio Pharmaceuticals Inc的前五大股東是誰？
Inovio Pharmaceuticals Inc的前五大股東如下：Dr. Jacqueline Elizabeth Shea, Ph.D.
有多少機構持有Inovio Pharmaceuticals Inc(INO)的股份？
截至2026Q1，共有266家機構持有Inovio Pharmaceuticals Inc的股份，合計持有的股份價值約為32.85M，占公司總股份的40.31% 。與2025Q4相比，機構持股有所增加，增幅為3035014.00。